Vantia Therapeutics appoints new chief executive

Andrew Crockett wins promotion after 12 months with pharma company

Vantia Therapeutics has appointed Andrew Crockett to the position of chief executive.

Since joining the Southampton, UK-based emerging pharmaceutical firm in 2009 as vice president of business development, Crockett has made a significant contribution to Vantia’s corporate development. He was previously with US specialist pharma company ZARS Pharma.

Martin Murphy, non-executive chairman of Vantia, said: ‘We are very pleased that Andrew Crockett has accepted the position as ceo. Vantia has made considerable progress over the past two years in advancing its pipeline of novel small molecule drug candidates into Phase II clinical trials. We wish Jim Phillips, the former ceo, well and appreciate his contribution to the team. The management team has created a solid platform for Vantia and we are therefore very pleased that Andrew will continue the great work that has been started.’

Crockett added: ‘We are looking forward to an exciting second half of the year when we expect important clinical data from our Phase IIa efficacy study in dysmenorrhoea and from our Phase IIb study in nocturia.’

Vantia Therapeutics develops novel, small molecule drugs targeting large, underserved medical markets. Formed in 2008 as a spin-out of Ferring Research’s small molecule r&d, it has two clinical phase products, VA106483 for the treatment of nocturia and VA111913 for the treatment of dysmenorrhoea, as well as preclinical and discovery programmes based on protease inhibition with potential in the areas of oncology and inflammation.

You may also like

Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
Regulatory

AbbVie submits new drug application to FDA for tavapadon in Parkinson’s disease treatment

The once-daily oral dopamine D1/D5 receptor partial agonist has been supported by positive Phase III TEMPO trial results that show symptomatic improvement across the Parkinson’s disease spectrum
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part II)

Part I of this article examined the critical role of palatability in patient adherence to treatment regimens, the underlying biological challenges of bitterness in medications and the innovative strategies used to create more acceptable and effective drug formulations
Manufacturing

Kindeva to showcase complex drug delivery expertise at CPHI 2025

Global CDMO highlights sterile injectable, pulmonary, nasal and dermal capabilities
Research & Development

AI-powered Viro3D becomes world’s largest database of human and animal virus proteins

Scientists at the MRC-University of Glasgow Centre for Virus Research have launched a free database containing structural models for 85,000 proteins from 4400 viruses, paving the way for faster development of vaccines and antiviral drugs
Research & Development

Prellis biologics partners with Eli Lilly to advance next-generation human antibody therapeutics

Prellis will combine its EXIS organoid and AntiGen AI platforms with Lilly’s research and development expertise, aiming to accelerate the discovery of fully human antibodies for multiple disease targets
Subscribe now